Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Dose-Finding Study of Oral LTT462 in Advanced Solid Tumors With MAPK Pathway Alterations
jRCT2080223152Phase 1Completed
- Sponsor
- Novartis
- Start
- Mar 2016
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of rineterkib in Nonhematologic neoplasms and cancer, sponsored by Novartis. Started Mar 2016; status: completed.
02
Drugs
rineterkib
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on jRCT2080223152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223152.